HalisKaanAkturkMD

PubMed

• Diabetes Technology Meeting 2023.
  Tiffany Tian, Rachel E Aaron, Ashley Y DuNova, Johan H Jendle, David Kerr, Eda Cengiz, Andjela Drincic, John C Pickup, Kong Y Chen, Naomi Schwartz, Douglas B Muchmore,...> ;Journal of Diabetes Science and Technology. 2024 Mar 25
• Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
  Satish K Garg, Gurleen Kaur, Christie Beatson, Janet Snell-Bergeon, Halis Kaan Akturk> ;Diabetes Technology & Therapeutics. 2024 Mar 21
• Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.
  Carlson, A., Liljenquist, D., Bergenstal, R., Sulik, B., Shah, V., Sulik, M., Zhao, P., Briggs, P., Sassan-Katchalski, R., Pinsker, J., Graham, T., Akturk, H.> ;Journal of Diabetes Science and Technology. 2024 Mar 5
• Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.
  Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T., Cohen, O., Akturk, H.> ;Diabetes Technology & Therapeutics. 2024 Mar 1
• 1 citations
  Emerging Technologies and Therapeutics for Type 1 Diabetes.
  Akturk, H., McKee, A.> ;Endocrinology and Metabolism Clinics of North America. 2024 Mar 1
• 1 citations
  Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study.
  Viral N Shah, Lauren G Kanapka, Halis K Akturk, Sarit Polsky, Gregory P Forlenza, Craig Kollman, Roy W Beck, Janet K Snell-Bergeon> ;Diabetes Technology & Therapeutics. 2024 Apr 1
• Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology.
  Shah, V., Trahan, A., Piquette, N., Wheatcroft, A., Schertz, E., Carmello, K., Mueller, L., White, K., Fu, L., Sassan-Katchalski, R., Messer, L., Habif, S., Constantin...> ;Journal of Diabetes Science and Technology. 2024 Feb 7
• Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.
  Akturk, H., Dong, F., Snell-Bergeon, J., Karakus, K., Shah, V.> ;Journal of Diabetes Science and Technology. 2024 Feb 5
• Limitations of 14-Day Continuous Glucose Monitoring Sampling for Assessment of Hypoglycemia and Glycemic Variability in Type 1 Diabetes.
  Akturk, H.> ;Diabetes Technology & Therapeutics. 2024 Feb 16
• Routine Blood Glucose Monitoring Does Not Predict Onset of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes.
  Michel, K., Couts, K., Karakus, K., Michels, A., Akturk, H., Robinson, W.> ;Diabetes Care. 2024 Mar 1
• 2 citations
  Insulin Pump Utilization in 2017-2021 for More Than 22,000 Children and Adults With Type 1 Diabetes: A Multicenter Observational Study.
  Ebekozien, O., Noor, N., McDonough, R., Hsieh, S., Miyazaki, B., Golden, L., Desimone, M., Hardison, H., Rompicherla, S., , Gandhi, K., Dei-Tutu, S., Akturk, H., Kambo...> ;Clinical Diabetes. 2024 Jan 1
• 8 citations
  Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collabora...
  Osagie Ebekozien, Ann Mungmode, Janine Sanchez, Saketh Rompicherla, Carla Demeterco-Berggren, Ruth S Weinstock, Laura M Jacobsen, Georgia Davis, Alexis McKee, Halis K ...> ;Diabetes Technology & Therapeutics. 2023 Nov 1
• Minimum Sampling Duration for Continuous Glucose Monitoring Metrics to Achieve Representative Glycemic Outcomes in Suboptimal Continuous Glucose Monitor Use.
  Halis K Akturk, Casey Sakamoto, Tim Vigers, Viral N Shah, Laura Pyle> ;Journal of Diabetes Science and Technology. 2023 Sep 25
• 1 citations
  Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade.
  Kagan E Karakus, Halis K Akturk, Janet K Snell-Bergeon, Viral N Shah, Alonso, G. T., Alonso, G. T., G Todd Alonso> ;Diabetes Care. 2023 Sep 1
• 1 citations
  Assessing the relationship between low-calorie sweetener use and quality of life measures in adults with type 1 diabetes.
  Halis K Akturk, Janet Snell-Bergeon, Kagan E Karakus, Viral N Shah> ;BMC Endocrine Disorders. 2023 Jul 11
• 3 citations
  Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in ad...
  Kagan E Karakus, Viral N Shah, David Klonoff, Halis K Akturk> ;Diabetes, Obesity & Metabolism. 2023 Nov 1
• 3 citations
  Prevalence of fear of hypoglycemia in adults with type 1 diabetes using a newly developed screener and clinician's perspective on its implementation.
  Megan E Peter, Nicole Rioles, Jingwen Liu, Katherine Chapman, Wendy A Wolf, Huyen Nguyen, Marina Basina, Halis Kaan Akturk, Osagie Ebekozien, Magaly Perez-Nieves, Jiat...> ;BMJ Open Diabetes Research & Care. 2023 Jul 1
• 6 citations
  Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population.
  Taylor M Triolo, Halis Kaan Akturk, Meghan E Pauley, Gregory P Forlenza, Casey Sakamoto, Laura Pyle, Brigitte I Frohnert, Alonso, G. T., G Todd Alonso, Marisa Sobczak> ;Diabetes Care. 2023 Jun 1
• Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
  Jeremy Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey, Halis K Akturk, Leslie J Klaff, Julio Rosenstock, Mickie H M Cheng, Bruce W B...> ;Nature Medicine. 2023 Nov 1
• Increasing Use of Diabetes Devices: What Do Health Care Professionals Need?
  Laurel H Messer, Tim Vigers, Halis K Akturk, Gregory P Forlenza, Kelsey B Huss, Angela J Karami, Emily Malecha, Sean M Oser, Sarit Polsky, Laura Pyle, Viral N Shah, R ...> ;Clinical Diabetes. 2023 Jan 1
• 1 citations
  Racial Disparities in Diabetes Technology Adoption and Their Association with HbA1c and Diabetic Ketoacidosis.
  Rebecca Baqiyyah Conway, Andrea Gerard Gonzalez, Viral N Shah, Cristy Geno Rasmussen, Halis Kaan Akturk, Gregory Forlenza, Janet Snell-Bergeon, Alonso, G. T., Alonso, ...> ;Diabetes, Metabolic Syndrome and Obesity. 2023 Jan 1
• 8 citations
  Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advance...
  Halis Kaan Akturk, Kasey L Couts, Erin E Baschal, Kagan E Karakus, Robert J Van Gulick, Jacqueline A Turner, Laura Pyle, William A Robinson, Aaron W Michels> ;JAMA Network Open. 2022 Dec 1
• 2 citations
  Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes.
  Viral N Shah, Halis K Akturk, Tim Vigers, Laura Pyle, Nick Oliver, David C Klonoff> ;Diabetes Technology & Therapeutics. 2023 Jan 1
• 16 citations
  Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
  Jeremy Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey, Halis K Akturk, Leslie J Klaff, Julio Rosenstock, Mickie H M Cheng, Bruce W B...> ;Nature Medicine. 2022 Oct 1
• Retained Diabetes Devices-A Literature Review.
  Nicole Y Xu, Kevin T Nguyen, Jan S Krouwer, Halis K Akturk, Viral N Shah, David C Klonoff> ;Journal of Diabetes Science and Technology. 2023 Nov 1
• Join now to see all

Journal Articles

• PD-1 Inhibitor Immune-Related Adverse Events in Patients with Preexisting Endocrine Autoimmunity  
  Halis Kaan Akturk, Aaron W Michels, The Journal of Clinical Endocrinology and Metabolism
• The Cortisol Stress Response Induced by Surgery: A Systematic Review and Meta‐Analysis  
  Halis Kaan Akturk, Irina Bancos, Clinical Endocrinology
• Linagliptin for the treatment of Type 2 diabetes  
  Tella SH, Akturk HK, Rendell M, Diabetes Management, 2014